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the PDTAs of the most representative Regions. The analysis investigates the follow-
ing Regional characteristics: establishment of a working group to define the PDTA, 
the gap of criteria for prescribing centers with the AISF guidelines, indication of 
therapeutic scheme for the different kind of patients, budget allocation, character-
istics of the management model and existence of a follow up system. Results: 
The results of the study show that, besides some common characteristics observed 
in all Regions (e. g. the presence of working group and criteria for the eligibility of 
patients and identification of prescribing centers), there is a substantial heteroge-
neity in Regional guidelines, especially regarding budget allocation, management 
model and follow up system. Indeed, if in some Regions like Basilicata and Veneto 
there is a specific budget allocation (respectively € 1,2 ml and € 12 ml in 2014), the 
management model is based on Hub and Spoke system and the follow up mecha-
nism is clearly set up, in other Regions like Lombardy and Liguria the guidelines are 
more vague, detailing only few criteria. These Regional differences are confirmed 
by other two data: the timespan between the market authorization of the Triple 
Therapy for HCV patients and the integration in Regional guidelines (e. g. 17 days 
in Veneto and 147 days in Emilia Romagna) and the number of prescribing centers 
per million inhabitants (6,92 in Basilicata and 1,85 in Veneto). ConClusions: The 
study demonstrate that, with a view to the future novel drugs, a common disease 
management model, including common guidelines and organizational model, is 
essential to avoid regional disparities in HCV therapies access.
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objeCtives: This retrospective study aimed to evaluate the actual chronic hepatitis 
C (CHC) treatment in Japan including interferon (IFN) treatment using Japanese 
claims data provided by Japan Medical Data Center Co., Ltd (JMDC). Methods: 
All claims data for 9,634 patients having a history of diagnosis related to CHC, 
liver cirrhosis (LC), or hepatocellular carcinoma (HCC) among Japanese claims data 
from January 2005 to October 2013 provided by JMDC were analyzed in this study. 
Treatment patterns and costs were evaluated in CHC patients newly diagnosed dur-
ing the study period. Results: 3,546 newly diagnosed CHC patients were included 
in this analysis. The median follow-up period was 21.0 months. The CHC treatment 
including IFN was not implemented in most cases (76.8%) during the follow-up 
period. The rate of IFN treatment was 7.0%. The combination therapy of IFN and 
ribavirin (RBV) was the most frequently used in IFN treatment. Median period of 
first line treatment to the discontinuation was 7.0 months in patients with IFN + 
RBV. The mean annual total cost in CHC patients with IFN, CHC patients without 
IFN with other drugs (e. g. ursodeoxycholic acid), CLC patients were 3.5 million yen 
($35,000), 2.0 million yen ($20,000), 3.1 million yen ($31,000), respectively. The mean 
annual number of outpatient visits in patients with IFN + RBV, patients without 
IFN with other drugs were 56.7 and 37.5 visits, respectively. ConClusions: The 
CHC treatment including IFN was not implemented in most cases despite having 
the CHC diagnosis. Furthermore, IFN treatment completion rate are low. One of the 
main causes of these facts would be adverse effects associated with IFN treatment. 
New drugs with fewer adverse effects are awaited for the future.
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objeCtives: The PALACE studies compared the efficacy and safety of apremilast 
(APR) with placebo in patients with active psoriatic arthritis (PsA) despite prior 
conventional disease-modifying antirheumatic drugs and/or biologics. The objective 
was to assess the impact of APR on physical functioning in patients enrolled in the 
PALACE trials. Methods: The pooled analysis included data from PALACE 1-3, three 
52-week, randomized, placebo-controlled studies evaluating APR in subjects with 
active PsA. Patients were randomized (1: 1: 1) to placebo, APR 20 mg BID (APR20), or 
APR 30 mg BID (APR30). Patients with < 20% reduction from baseline in swollen and 
tender joint counts at Week 16 were required to be re-randomized (1: 1) to APR20 or 
APR30 if initially randomized to placebo, or continued their initial APR dose. At Week 
24, all remaining placebo patients were re-randomized to APR20 or APR30. The anal-
ysis reports data from the APR-exposure period (Weeks 0 to 52). Physical function, 
a pre-specified secondary end point, was measured using the Health Assessment 
Questionnaire-Disability Index (HAQ-DI) and the 36-item Short-Form Health Survey 
version 2 Physical Functioning (PF) domain and physical component summary (PCS) 
scores. Results: At Week 16, the observed physical function change from baseline 
was improved with APR20 and APR30 vs. placebo, as measured by the HAQ-DI (-0.17 
[P< 0.001] and -0.23 [P< 0.001] vs. -0.07), PF (2.73 [P< 0.007] and 4.08 [P< 0.001] vs. 1.52), 
and PCS (3.44 [P< 0.002] and 4.46 [P< 0.001] vs. 2.03). At Week 52, among patients who 
were treated with APR continuously, the physical function change from baseline for 
APR20 and APR30 was improved, as measured by the HAQ-DI (-0.30 and -0.33), PF 
(5.55 and 5.53), and PCS (6.37 and 6.23). ConClusions: Patients treated with APR30 
reported improvement in physical function compared with placebo, as measured by 
the HAQ-DI, PF, and PCS. This response was maintained over 52 weeks.
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tion (6-month ER visits and hospitalizations). Comparisons in each of these health-
related topics were made between respondents with IBS-C versus non-FGID, asthma, 
migraine, and RA. Comparisons controlled for age and gender. Results: Prevalence 
of IBS-C was 0.67%, 1.03%, and 0.91% in the US, UK, and France, respectively. Most 
respondents were female (> 65%) and mean age ranged from 47.7 to 49.8 years. In 
each country, mean SF-12 physical (PCS) and mental (MCS) summary scores were 
statistically (p< 0.001) and clinically meaningfully (> = 2.5) lower than the non-FGID 
group. With few exceptions, PCS and MCS scores of IBS-C were significantly (p< 0.05) 
lower than scores for asthma, migraine, and RA. In each country, IBS-C reported 
significantly (p< 0.001) greater absenteeism and worse presenteeism and greater 
overall work productivity loss and daily activity impairment than non-FGID, and 
with few exceptions, worse than asthma, migraine, and RA. Lastly, in each country 
the number of ER and hospital visits was significantly higher (p< 0.01) for IBS-C 
compared to non-FGID and, with few exceptions, higher than asthma, migraine, 
and RA. ConClusions: In the three countries respondents with IBS -C showed 
significant and clinically meaningful deficits in HRQoL and work productivity and 
elevated health care utilization compared with other chronic conditions.
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objeCtives: The purpose of this study was to evalute the safety and effectiveness 
of serial transverse enteroplasty (STEP). Methods: The clinical utility of STEP was 
first reviewed in three textbooks and secondly the safety and the effectiveness of 
the STEP were assessed based on a systematic revew. 575 articles were searched 
using database (KoreaMed, Ovid-MEDLINE, Ovid-EMBASE and Cochrane Library, etc.) 
and eliminated acoording to inclusion/exclusion criteria, duplicate search results. 
Finally, 9 articles (2 cohort studied and 7 case studies) were used. Two evaluators 
performed independently throuout each process. The article’s quality evaluated by 
the SIGN’s tool and the grade of recommendation were selected. Results: A review 
of the textbooks revealed that STEP is conducted on patients with refractory SBS. And 
the advantages of STEP are that it is technically straightforward, can form a uniform 
bowel channel regardless of variable underlying bowel dilation, and can be repeated 
if the bowel subsequently radilated. The safety of STEP was assessed based on pro-
cedure-related complications in 6 articles. The complication rate of STEP was overall 
6.3~25%, bleeding 6.3~12.5%, obstruction 6.3~22%, anastomosis leak 2.3~16.7% and 
stricture 11~20%. The complication rate of the STEP versus the Bianchi LILT was no 
significantly difference. The effectiveness of STEP was assessed based on the enteral 
autonomy and survival rate in 9 articles. There was a trend toward a decreased rate of 
PN after STEP. As a result, the 33~56% patients who underwent STEP were weaned off 
within one year and 83~88% after one year. Survival was 83% with maximum follow-
up of 68 months. ConClusions: The safety of STEP was at an acceptable level as 
complications reported in studies generally occur after an intestinal operations and 
such problems can be corrected surgically. The clinical utility of STEP was described 
in the textbooks as a non-transplantation procedure and all the selected articles 
was reported on wean-off parenteral nutrition. Therefore, there is evidence for the 
safety and effectiveness of STEP performed on patients with refractory short bowel 
syndrome for promoting eneteral nutrition (Recommendation grade C).
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objeCtives: Ulcerative colitis is one of 56 designated diseases for the Specified 
Disease Treatment Research Program that provides co-payment reduction or exemp-
tion according to disease severity and patients’ income levels. Under the fee-for-service 
payment system, such financial assistance program may influence drug utilisa-
tion. The objective of this study is to assess the overall drug prescribing pattern for 
ulcerative colitis. Methods: Claims data with indication for ulcerative colitis were 
extracted from the Social Health Insurance claims data processed from December 2009 
to February 2010 and from February to April 2011. Extracted data were analysed and 
compared in terms of patients’ age, types of public subsidy, prescribed places (clinic/
hospital or pharmacy) and pharmacologic classes. Results: Total numbers of patients 
were 67,480 for the former duration and 84,450 for the latter duration. Among them, 
patients who were entitled to the Specified Disease Treatment Research Programme 
were 47,103 and 60,231 respectively. The most commonly used drug was mesalazine 
which accounted for 56% and 59%. Infliximab was prescribed mainly for those entitled 
to the Specified Disease Treatment Research Program. Of total infliximab dose, 23 % 
and 30% were with steroid and 33% and 38% were with mesalazine. Generic utilisa-
tion rate for patients entitled to the Specified Disease Treatment Research Programme 
or other financial assistance programs was low. ConClusions: The highest utiliza-
tion of infliximab and low generic utilization were observed for patients entitled to 
the Specified Disease Treatment Research Programme. Prescribing pattern of drugs 
suggested that some cases did not follow clinical guidelines. Adherence to clinical 
guideline recommendations should be promoted.
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objeCtives: The aim of this study is to describe the differences in Patients 
Diagnostic Therapeutic Pathways (PDTA) among Italian Regions, as the Italian sce-
nario shows substantial differences in terms of Regional guidelines, organization 
and allocated budget. Methods: The Regional policies were examined analyzing 
